Skye Bioscience to host KOL event on CBeyond Phase 2a clinical data readout

Skye Bioscience (SKYE) will host a virtual KOL event, titled “Expert Panel on Peripheral CB1 Inhibition as a Mechanism for Weight Loss,” on Thursday, September 4th at 8:00 AM ET, to discuss expectations and details of upcoming topline results from the Phase 2a CBeyond trial of nimacimab, a first-in-class peripheral CB1 antibody for obesity. KOL Event Highlights – The event will feature obesity key opinion leaders and will cover expectations and details of the upcoming Phase 2a CBeyond topline results readout including: What constitutes success in Skye’s Phase 2a proof-of-concept study; Mechanism and potential role of peripheral CB1 inhibition as a differentiated and complementary anti-obesity therapeutic pathway to other mechanisms of action; Highlights of newly generated preclinical data with nimacimab; Q&A session. CEO Punit Dhillon commented, “This KOL event is about clarity ahead of CBeyond’s Phase 2a topline data and we are delighted to feature a discussion between management and leading clinical and scientific experts. The dialogue will serve to frame what constitutes success in this proof-of-concept study, discuss the important considerations of safety and tolerability, notably gastrointestinal outcomes, which are an important benchmark in the obesity field, and neuropsychiatric considerations that are pertinent to the CB1 class, and highlight how we will read the data against nimacimab’s target product profile. We’ll also share new preclinical insights that inform our translational view. We are not previewing clinical results, however, together, these insights will outline the potential of nimacimab to advance into Phase 2b development and shape its role within the evolving obesity treatment landscape.”